Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections
+ Market Ready CBD Derma Cosmetic Brand And Patent-Pending CBD Pain Relief Brand
Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients
The report outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19. Specifically, the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.
Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome
The paper entitled, "Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome" published in the Journal of Cellular and Molecular Medicine on October 15, 2020, demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms.
Innocan Pharma received U.S. FDA approval for their over the counter CBD pain relief line
Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection.
Cannabis-infused treatment for Covid-19 under development
InnoCan Pharma working with Tel Aviv University on products using CBD-loaded exosomes for lung inflammation and possibly epilepsy.